CPHI — CHINA PHARMA HOLDINGS INC (Healthcare >> Drug Manufacturers - Specialty & Generic)
CPHI FAQ
What is CPHI's ROE?
CHINA PHARMA HOLDINGS INC reports a Return on Equity (ROE) of -9.53%.
What is CPHI's dividend yield?
CHINA PHARMA HOLDINGS INC offers a dividend yield of 0.00%.
What is CPHI's Deepscope Quality Score?
Deepscope rates CPHI's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy CPHI?
Deepscope's AI Timing Score for CPHI is 87 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does CPHI belong to?
CHINA PHARMA HOLDINGS INC is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NYSE MKT exchange.
|
USD 0.72
Price
-0.11
(-12.90%)
Day Change
|
|
|---|
CPHI, the overall quality is not good ( Quality = 38) but the timing to buy is ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 94 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.72 |
| PBV / Sector |
0.88 / 2.76
GREAT
|
| Earning Per Share | -0.08 |
| PE / Sector |
N/A / 23.64
|
| PEG or PE/Growth / Sector |
N/A / 0.13
|
| Average 1M Daily Value |
0.73 M
GREAT
|
| Average 1W Daily Value |
0.04 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
56% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:09:30 |
| Symbol | CPHI |
| Name | CHINA PHARMA HOLDINGS INC |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NYSE MKT |
| Listed Shares | 40.52 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 32.77 / 9,835.56 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: No. 17, Jinpan Road, Haikou, China, 570216
Phone: 86 89 8668 11730
Website: https://www.chinapharmaholdings.com
Employees: 215
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection for edema diseases, hypertension, acute renal failure, hyperkalemia, hypercalcemia, and acute drug poisoning; and Candesartan for hypertension. It offers Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and Pseudophedrine Hydrochlorida sustained release tablets, as well as Hepatocyte growth-promoting factors, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. In addition, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection for nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It supplies its products to hospitals and OTC pharmacies through provincial and municipal pharmaceutical logistics companies. The company is based in Haikou, the People's Republic of China.
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
Google